Age-Related Changes in the Hepatic Pharmacology and Toxicology of Paracetamol

Sarah J. Mitchell, 1, 2, 3, 4, 5 Alice E. Kane, 2, 3, 4, 5 and Sarah N. Hilmer 2, 3, 4, 5

1 Laboratory of Experimental Gerontology, National Institute on Aging, National Institutes of Health, Baltimore, MD 21224-6825, USA
2 Kolling Institute of Medical Research, The Royal North Shore Hospital, St. Leonards, NSW 2065, Sydney, Australia
3 Department of Clinical Pharmacology, The Royal North Shore Hospital, Pacific highway, St. Leonards, NSW 2065, Sydney, Australia
4 Sydney Medical School, University of Sydney, St. Leonards, NSW 2065, Sydney, Australia
5 Laboratory of Ageing and Pharmacology, Level 12 Kolling Building, The Royal North Shore Hospital, Pacific Highway, St Leonards NSW 2065, Australia

Correspondence should be addressed to Sarah J. Mitchell, sarah.mitchell@sydney.edu.au

Received 31 January 2011; Accepted 29 March 2011

1. Introduction

Paracetamol remains one of the most studied agents that cause hepatotoxicity due to its clinical relevance and to its dose-dependent hepatotoxicity in animals and humans [1]. Paracetamol is an effective analgesic agent and represents the first-line analgesic therapy for nonmalignant pain [2]. However, the use of paracetamol is limited by its potential to cause hepatotoxicity. With old age, there is an increase in disease for which medications may provide benefit; however, the incidence of serious adverse drug reactions (ADRs) also increases with increasing age, even after controlling for increased medication use [3]. In older adults, most ADRs, including drug-induced liver injury (DILI), are dose-related [4]. Therefore, optimising the safety and efficacy of medication use in older adults is important.

For most drugs, the evidence base for dose adjustment in older people is limited to pharmacokinetic studies in small populations of healthy volunteers. There is very little data available on the clinical outcomes of dose adjustment, particularly in the frail aged. In all age groups, an important susceptibility factor for hepatotoxicity is genetic variability [5]. In older people, this may be compounded by the multi-factorial large interindividual variation in response to medications further increasing the risks of toxicity and poor efficacy [5]. This is a particular concern in frailty, a condition of increased vulnerability to adverse events [6]. Although monitoring for clinical response is essential to optimise efficacy and reduce toxicity, the detection of adverse effects of medications in older patients may be complicated by nonspecific presentation as “geriatric syndromes” [7]. In addition, age-related changes in the pharmacokinetics and
pharmacodynamics of drugs further compounds the risk of toxicity. In older adults, the clinical increased risk of paracetamol hepatotoxicity is likely to be related to dosing that does not account for decreased liver volume with age, and to frailty and malnutrition [8]. However, recent discoveries about the ageing liver identify novel mechanisms for age-related changes in hepatic pharmacology and toxicology (summarised in Figure 1). In this paper, we describe the age-related physiological changes, with particular attention to the liver specific changes, and how they can impact on hepatic pharmacology and toxicology of paracetamol.

2. Physiological Changes in Ageing

The most marked pharmacologic change with ageing is increased interindividual variation. The most significant pharmacokinetic change in ageing is related to the decreased hepatic mass, uptake, and blood flow [9, 10] and to decreased renal function [11], impairing the clearance of many drugs and their metabolites [12]. Table 1 summarises the physiological changes associated with ageing and frailty that can impact on the pharmacokinetics and pharmacodynamics of drugs.

Changes in the pharmacodynamics of drugs in old age is related to changes in drug receptors, physiologic reserve and in response to injury [12]. However, these changes have not been as well characterised in ageing as the pharmacokinetic changes. The cardiovascular and central nervous systems are the two best described. A reduction in the responsiveness of the cardiac and β-adrenergic system has been observed in older adults [14]. In the central nervous system, the numbers of dopaminergic neurons and dopamine D2 receptors decrease with age resulting in extrapyramidal side effects [26]. Studies in animal models suggest that increased sensitivity to narcotic and anaesthetic agents may be due to alteration of opioid receptors (decreased μ-opioid receptor density and increased affinity) in old age [15].

Ageing is associated with changes in body composition, including a reduction in total and lean body mass, and a relative increase in fat mass [12, 27], which may affect the volume of distribution and loading dose of drugs. Sarcopenia, defined as loss of muscle mass and strength with ageing, increases with age and is associated with frailty [5, 27]. It can be the result of concomitant diseases, neuroendocrine dysregulation and/or chronic inflammation [27].

3. Liver Specific Changes in Ageing

The age-related reduction in liver size is noted to be in the order of 25 to 35%, which has been confirmed in many species including humans [9, 28–30]. The main age-related change in the physiology of the liver is a substantial reduction in blood flow of about 40% [29] which has been postulated to be due to leukocyte accumulation in the sinusoids and narrowing of sinusoidal lumens due to pseudocapillarisation and dysfunction of the liver sinusoidal endothelial cells (LSECs) [31].

3.1. Pseudocapillarisation of the Liver Sinusoidal Endothelium. The sinusoidal endothelium is a thin fenestrated endothelium lacking a basal lamina and punctuated with fenestrations of 50 to 200 nm in diameter grouped together in clusters known as liver sieve plates [32–35]. With ageing, the LSECs undergo ultrastructural changes termed pseudocapillarisation [16] that include that loss of fenestrations, thickening of the endothelium, perisinusoidal collagen deposition, and basal lamina formation [16, 36, 37], which may affect hepatic drug disposition. Recently, the endocytic capacity of LSECs was reported to be reduced in old
Table 1: Physiological changes associated with ageing and frailty that can impact on the pharmacokinetics and pharmacodynamics of drugs.

| Physiological change                  | Pharmacokinetic consequences                                      |
|---------------------------------------|--------------------------------------------------------------------|
| ↑ Gastric pH                          | Delay in absorption no change in the overall                      |
| ↓ Secretory capacity                  |                                                                    |
| ↓ Gastrointestinal blood flow         |                                                                    |
| ↓ Absorption surface                  |                                                                    |
| ↓ Gastrointestinal motility           |                                                                    |
| ↑ Body fat                            | ↑ Vd and t₁/₂                                                        |
| ↑ Lean body mass                      | ↑ Plasma concentration and ↑ Vd of hydrophilic drugs               |
| ↓ Total body water                    | ↑ Free fraction of highly protein-bound acidic drugs               |
| ↓ Serum albumin                       | ↓ Free fraction of basic drugs                                     |
| ↑ α1-acid glycoprotein                |                                                                    |
| ↓ Hepatic blood flow                  | ↓ First-pass metabolism                                            |
| ↓ Hepatic mass                        | Phase I metabolism of some drugs may be slightly impaired          |
| ↓ CYP content                         | ↓ / ↔ Phase II in fit older adults, ↑ in frail                    |
| Pseudocapillarisation of the liver    | ↑ / ↔ Phase III                                                   |
| sinusoidal endothelium                |                                                                    |
| ↓ Renal blood flow and glomerular     | Renal elimination of drugs can be impaired                        |
| filtration rate                       | altering drug half-life                                            |
| ↓ Tubular secretion                   |                                                                    |
| Physiological change                  | Pharmacodynamic consequences                                      |
| ↓ Blood supply to brain               | ↑ Sensitivity to centrally acting drugs such as benzodiazepines    |
| ↓ Baroreceptor activity               |                                                                    |
| ↓ Resting heart rate, stroke volume,  | ↓ Response to beta blockers such as metoprolol                    |
| and cardiac output                    |                                                                    |
| ↓ Plasma renin                        |                                                                    |
| ↓ Urine aldosterone                   |                                                                    |
| ↓ Hepatic GSH                         | ↓ Detoxification ability of the liver                              |
| Dysregulation of Kupffer cells        | Dysregulation of immune response to drugs and other toxins       |
| Dysregulation of the immune system    |                                                                    |
| Mitochondrial dysregulation           | ↑ Susceptibility to DILI                                            |

†, decreased; †, increased; ↔, no change; ?, unknown; CYP, Cytochrome P450; Vd, volume of distribution; t₁/₂, half-life; DILI, drug-induced liver injury; GSH, glutathione; adapted from [13] and references [2, 11–23].

age, which may be especially important in situations with increased circulatory waste loads [38].

3.2. Dysregulation of Kupffer Cell Activation. Kupffer cells (KCs) are the resident phagocytic macrophages in the liver, which represent the largest population of fixed macrophages in the body and account for approximately 20% of nonparenchymal cells in the liver [39]. KCs have diverse functions, including phagocytosis, endocytosis, immuno-modulation, and synthesis and secretion of numerous biologically active mediators [39, 40]. Furthermore, the dual role of activated KCs in releasing both pro- and anti-inflammatory mediators during the different stages of liver injury and regeneration has been demonstrated [39]. It is likely that dysregulation of the KCs with ageing may alter the inflammatory response to DILI; however, there is conflicting evidence. For example, while there is a basal increase in the numbers of KCs in old rats [40], their activation in response to toxic doses of cadmium and endotoxin is decreased [41, 42]. However, KCs in lipopolysaccharide-treated had showed no difference in activity with the phagocytosis of fluorescent beads being similar across age groups [43]. The role of KCs in paracetamol-induced hepatotoxicity will be discussed below.

3.3. Age-Related Changes in Hepatic Metabolism Affect Drug Clearance. Age-related changes in hepatic metabolism will affect drug clearance and toxicity. In general, there is a reduction in Phase I metabolism in vivo with normal ageing...
in the order of 30%–50% [24]. Phase II metabolism appears to be maintained in the healthy elderly but reduced in the frail [24]. The Phase III transporters have not been well described in humans.

The Phase I drug metabolising enzymes (DMEs) consist of the superfamily of CYP450 enzymes. Animal studies have indicated that total CYP content is reduced in aged rats [44]. In humans, it has been suggested that CYP450 content declines at a rate of 0.07 nmol/g of liver after 40 years of age [45]. However, there is conflicting evidence on the CYP activity with age (Table 2). For example evidence from liver biopsies of surgical patients indicate that normal ageing does not affect the activity of human CYP2E1, other evidence suggests that CYP2E1 activity may decrease with age [46]. Furthermore it has been suggested that the induction of CYP2E1 could also be affected by advanced age [47]. Interestingly it has shown that sex and concurrent medications have a greater effect than chronological age on CYP3A substrates in older patient populations [48, 49]. Frail older persons do not have slower erythromycin breath test results compared with non frail older persons potentially indicating preserved CYP3A activity as well as P-glycoprotein (P-gp) transport, in frailty [48].

However, it can be assumed that there is some minor impairment in CYP activity with ageing given that there is a small decline (in the order of 20% observed in patients aged 25–75 years) in antipyrine clearance with age and antipyrine is metabolised by multiple CYPs [45, 50, 51]. The effect of disease, concurrent medications and frailty, and comorbidity on CYP activity still needs to be investigated given that these studies were conducted in relatively healthy volunteers.

Phase II metabolism acts to increase hydrophilicity of the compounds, and thereby enhance excretion in bile and or urine [63]. Enzymes include the sulfotransferases, UDP-glucuronosyltransferases (UGTs), and glutathione s-transferases (GSTs). Most data suggest that the Phase II conjugation pathways are not altered by ageing [13, 52]. However, a recent reanalysis of pharmacokinetic studies in old age found that the apparent preservation of Phase II metabolism may have been confounded by inadequate consideration of protein binding [64]. Therefore, suggesting that Phase II metabolism is impaired in healthy ageing [64]. This is consistent with animal studies in which transcript profiles for the glucuronidation, sulfation, and glutathione conjugation genes are reportedly decreased in aged Fischer 344 rats [65].

The Phase III hepatic pathway encompasses the transporters on the basolateral and apical sides of the hepatocytes, which function to remove xenobiotics from the portal blood and to excrete them or their metabolites in to bile or blood, and includes the bile transporter P-gp [66–68]. The expression of hepatic transporters in response to drug toxicity is poorly described in old age and will affect biliary excretion of drugs and their metabolites. There are few human studies on Phase III hepatic metabolism in ageing. P-gp expression is increased in aged Fischer-344 male, but this is specific to the liver [69]. A small study of healthy volunteers found decreased P-gp activity in the blood brain barrier of five older healthy volunteers, age range 59–68 years [70]. It must be noted that the wide genetic interindividual variation in expression of P-gp [71] may be further confounded by the increasing heterogeneity with age [67].

### Table 2: Changes in the cytochrome P450 activity with ageing.

| CYP Enzyme | Change with ageing | Probe drug used | Confounding factors |
|------------|--------------------|-----------------|-------------------|
| CYP1       | ↓                  | Theophylline    | Ethnic polymorphisms, sex differences, lifestyle, and disease |
| CYP2       | ↓ (~25%)           | Phenyltoin, Warfarin, Omeprazole | Age-related effects, and unrecognised environmental effects, and pharmacogenetic variation |
| CYP2C9     | ↓ Older women      | Dextromethorphan Haloperidol | Genetic polymorphisms |
| CYP2C19    | ↓ Aged rats        | Chlorzoxazone   | Gender-conflicting results Polymorphisms |
| CYP2D6     | ↓ Old Japanese men | Cyclosporine, Erythromycin, Verapamil, Midazolam | Inducers |
| CYP3A      | ↓ Aged rodents     |                | Inducers |
| CYP3A4     | ↓ CL in women, no age effects |                | Metabolised by CYP3A4, 1A2 and 2C8/9 |
| Multiple   | ↓                  | Antipyrine      |                |

CYP; cytochrome P450; ↓, decreased; ↑, increased; ↔, no change; ?, unknown; CL, clearance; adapted from [13, 52–55].
Ageing has been associated with decreased mRNA expression of organic anion-tran sporting polypeptide (Oatps) including Oatp1a1, Oatp1b2, and Oatp2b1, as well as organic cation transporters (Octs) Oct1, and sodium/taururonolate-cotransporting polypeptide in aged mice [53]. Furthermore, the mRNA expression of several efflux transporters including Multidrug resistant protein (Mrp)-2, Mrp6 and Mrp3 have been shown to be significantly reduced in old age in mouse livers [53]. However, what this means in terms of activity and how it translates to humans still needs to be determined.

3.4. Mitochondrial Structure and Function in Old Age. Changes in mitochondrial structure and function in old age [72] alter the response to reactive oxygen species and cell death pathways. It appears that malfunction and decrease of biogenesis of mitochondria seem to exert some of the most potent effects on the organism [72]; however, the exact mechanism still needs to be elucidated.

3.5. Glutathione in Old Age. Glutathione (GSH) has several important functions including detoxification of electrophiles, maintenance of essential thiol status of proteins and other molecules, scavenging of reactive oxygen species (ROS), providing cysteine as well as modulation of critical cellular processes such as DNA synthesis, microtubule-related processes, and immune function [73, 74]. These reactions are catalysed by the GSTs [74]. Hepatic GSH is decreased in aged rats [75, 76] and in aged mice [77, 78]. Serum GSH and the levels of its associated enzymes are decreased in ageing in humans [79]. In rats, this age-related decrease has been shown to be further exacerbated by ethanol consumption [80] which may be a problem in chronic alcoholics.

3.6. Nrf-2 in Old Age. Nuclear factor E2-related factor 2 (Nrf-2) regulates the transcription of antioxidant genes including genes for the Phase II conjugation enzymes (e.g., UGTs), glutathione homeostasis, stress response, and transporter proteins through the antioxidant-responsive element. Nrf-2 downregulation with ageing has been suggested as one mechanistic explanation for reduced Phase II metabolism in old age [81].

4. Implications of the Age-Related Alterations in Hepatic Pharmacology and Toxicology

A decline in liver volume and liver blood flow with ageing may be a major component of age-related alterations in the liver, leading to the fall in clearance of many of the drugs whose pharmacokinetics have been found to be altered with age [9]. Hepatic clearance is influenced by substrate delivery to the liver parenchymal cells and by the inherent metabolic capacity of the hepatocytes. Therefore, any change in the LSECs, including pseudocapillarisation, may alter drug transfer from the blood to hepatocytes. Age-related pseudocapillarisation has been shown to be associated with impaired transfer of lipoproteins as well as with paracetamol across the fenestrations [82, 83] as illustrated in Figure 2.

Changes in the inherent ability of the liver to detoxify toxic metabolites will lead to increased susceptibility to DILI. This may be due to the age-related dysfunction and reduced biogenesis of mitochondria [72], and/or the age-related reduction in Phase II metabolism and reduced hepatic GSH in old age [84], secondary to reduced transcriptional activity of Nrf-2 [81].

Interestingly “the mitochondrial hypothesis” implies that the gradual accumulation of initially silent mitochondrial injury which, when a critical threshold is reached, abruptly triggers liver injury [85]. This could explain why DILI does not affect all individuals equally (duration of exposure is not the same for all individuals), the delay in developing DILI by weeks or months (accumulation of deficits to reach a threshold), and why increasing age is a risk factor (due to duration of exposure or mitochondrial changes in ageing) [86]. The role of these changes and their effect on paracetamol-induced liver injury will be discussed below.

5. Paracetamol-Induced Liver Injury in Ageing

Paracetamol (or acetaminophen) is a p-aminophenol derivative which was discovered at the John Hopkins University in 1877 [87]. Due to its safety profile, paracetamol is particularly useful in older adults; however, caution must be taken because of its potential for toxicity [88]. Paracetamol has the potential to cause liver damage and even liver failure in overdose and now case reports are emerging of people developing significantly increased ALT concentrations following therapeutic dosing [89], even in the absence of risk factors [89, 90]. Paracetamol causes dose-dependent hepatotoxicity through the metabolic bioactivation of the parent drug to toxic metabolite [1].

5.1. Epidemiology. A recent systematic investigation by the WHO Collaborating Centre for International Drug Monitoring reported that since 1969, paracetamol has been one of the five most common drugs associated with fatalities [91]. After 1990, there was a shift from halothane (immuno-allergic DILI) being the most common drug associated with a fatal outcome to paracetamol (dose-dependent DILI) [91, 92]. Table 3 shows selected reports of paracetamol-induced hepatotoxicity deaths and transplants, with special reference to those aged >60 years, in the United Kingdom, United States, Canada, Malaysia, and Australia for the period 1989–2010. In the United States, paracetamol is responsible for approximately half of the cases of acute liver failure [1].

5.2. Hepatotoxicity. At therapeutic doses paracetamol metabolised primarily in the liver to nontoxic metabolites via Phase II metabolism (conjugation) with glucuronide and sulphate, or cysteine [93]. A small amount of drug undergoes Phase I CYP450-mediated N-hydroxylation to form N-acetyl-p- amino-benzoquinone immine (NAPQI), a toxic metabolite [93–95]. The most important isomorf responsible for this CYP450-mediated metabolism is CYP2E1, but
Current Gerontology and Geriatrics Research

![Diagram of liver sinusoid and pseudocapillarisation]

**Figure 2:** Age-related pseudocapillarisation of the liver sinusoid impairs the transfer of lipids (chylomicrons remnants) and paracetamol across the fenestrated liver sinusoidal endothelial cells (LSECs). Adapted from Le Couteur et al., 2002 (20).

| Source | Approximate population Size | Cases/million population/year | % of Reports for those aged> 60 years | % of Reports unintentional | Reference |
|--------|-----------------------------|-----------------------------|----------------------------------|---------------------------|------------|
| Spontaneous ADR reports, AUS 1990–2010 | 17–22.5 million | 0.04 deaths | 37.5% deaths | NR | Pers. Comm. Graeme Harris, ACSOM, 24/8/2010 |
| Ballarat Hospital Records, AUS 2000–2003 | 0.2 million | 240 hospitalisations | 2.6% hospitalisations | 4.7% | [56] |
| Penang General Hospital, Malaysia 2000–2002 | Approx 1.3 million | 42.3 cases of poisoning | 1.2% of poisoning cases | 33.3% | [57] |
| Calgary, Canada 1995–2004 | 1.1 million | 140.2 hospitalisations | 4.5% hospitalisations | 13% | [58] |
| US Transplant Centres 1998–2001 | 17 tertiary care centres | NR | 6% ALFs 6.8% deaths | 57% ALFs | [59] |
| US 1990–2001 | 250 million | 1.83 deaths | 4% hospitalisations 14% deaths | 23 % hospitalisations 22% deaths | [60] |
| Cardiff, UK 1989–2002 | Approx 2.9 million | 185 hospital admissions | 1.6 % of admissions in adults 60–69 years 1.8% of admissions in adults >70 years | All intentional | [61] |
| England and Wales 1993–1998 | NR | 15720 deaths, 13% due to paracetamol alone, 5.8% due to paracetamol and other drugs | 11.5% deaths per million males during 1993–1998 14.2% deaths per million females during 1993–1998 | NR | [62] |

NR, not reported; US, United States; UK, United Kingdom; AUS, Australia; ADR, adverse drug reaction; ACSOM, Advisory Committee on the Safety of Medicines; ALF, acute liver failure; APAP, paracetamol.

CYP3A4 and CYP1A2 are also involved [93]. Under normal circumstances, NAPQI combines with sulphhydryl groups in hepatic glutathione and is neutralized [93, 96]. The major conjugates, glucuronide and sulfate being more water-soluble than the parent drug, are both eliminated from the liver and blood mainly via the urine, with a small amount of the glucuronide conjugate eliminated via the bile [93, 97, 98]. Following ingestion of large amounts of paracetamol, conjugation pathways become saturated resulting in increased use of the CYP450 pathway, increased NAPQI formation and increased depletion of hepatic glutathione [97, 99]. The direct mechanism of paracetamol-induced liver injury involves the formation of the toxic metabolite, NAPQI, from paracetamol by the enzymes of the liver [100].
NAPQI can directly interact with macromolecules in the cell causing protein dysfunction, lipid peroxidation, damage of DNA, and oxidative stress [100]. Dysfunction of mitochondria may also result thereby in interrupting energy production and disrupting ionic gradients and intracellular calcium stores to result in cell death and liver damage [100, 101].

The formation of reactive metabolites such as NAPQI is an important initiating factor for DILI. It is the inflammatory immune response and the balance between the protective and toxic signalling processes of the cells involved in this response that determines the severity and progression of liver injury [102]. Holt and Ju (2006) suggest that hepatocyte stress or death, as a result of the reactive metabolite induced damage, causes the release of signals that stimulate activation of the innate immune cells of the liver [100]. KCs, natural killer cells and neutrophils, are part of this response [103] and are recruited and activated. These cells produce proinflammatory cytokines and mediators such as tumor necrosis factor (TNF)-α, interleukin (IL)-1β and interferon (IFN)–γ [104–106]. Other mediators released by these immune cells are protective and anti-inflammatory such as IL-10 [106] and IL-6 [107]. However, there is much disagreement between the studies, and the exact role of each of the cell types and mediators in DILI generally, as well as in paracetamol-induced liver injury, has yet to be fully determined [100].

5.3. The Role of Kupffer Cells in Paracetamol Induced Hepatotoxicity. Paracetamol-induced hepatotoxicity has been attributed in part to activation of KCs secondary to hepatocyte damage initiated by NAPQI [108, 109]. It is believed that Kupffer cell activation results in the release of a wide range of proinflammatory mediators capable of causing further hepatic injury [110]. However, there is controversial evidence surrounding the role of KCs in paracetamol-induced hepatotoxicity. The numbers of these F4/80 positive cells in the liver are increased following paracetamol treatment [111, 112]. Yet, macrophage dephagy has been shown to have a role in both the protection [113] and potentiation of liver injury [114]. Pretreatment of rats with macrophage inactivators, such as galolinum chloride and dextran sulfate, has been shown to decrease hepatic injury from paracetamol in rats [110, 115]. This was also observed in a mouse model of hepatotoxicity [113, 114] with the protection being ascribed to decreased formation of reactive oxygen and nitrogen species [113]. The use of liposome-encapsulated clodronate to deplete KCs from the liver [116] revealed a hepatoprotective role in a mouse model of paracetamol-induced liver injury [114]. Furthermore, the significant decrease in the levels of several cytokines and mediators, including IL-6, IL-10, and IL-18-binding protein may suggest that KCs mediate their beneficial role via the release of such soluble factors [114]. In support of this, it was recently suggested that a disturbance in the T-helper (Th)-1/Th-2 cytokine balance could play an important role in the pathogenesis of paracetamol-induced liver injury [117].

5.4. The Role of LSECs and Microvasculature Disturbance in Paracetamol Hepatotoxicity. It was recently suggested that the hepatoprotective role of KCs may be mediated, in part, via regulation of LSEC homeostasis and integrity [118]. In mice, the early events occurring in the hepatic microvasculature following paracetamol treatment include LSEC injury, which was exhibited by the swelling of LSECs, and the penetration of erythrocytes into the extra sinusoidal space [119]. Interestingly, these findings precede hepatocyte injury and suggest that the LSECs are a direct and early target during paracetamol hepatotoxicity [119, 120]. Furthermore, the structural and functional changes in LSECs could contribute to the initiation or progression of paracetamol-induced liver injury [119]. Taken together, this indicates that reduced sinusoidal perfusion and increased Kupffer cell activity participate in the development of liver injury elicited by paracetamol [119].

5.5. The Effect of Ageing on Susceptibility to Paracetamol-Induced Liver Injury. Risk factors for paracetamol hepatotoxicity include malnutrition which results in depletion of glutathione [121], chronic alcohol consumption, which acts to both reduce glutathione stores and induce CYP2E1 [122], and concurrent use of CYP-inducing drugs such as Isoniazid [123]. Inflammation as a result of bacterial or viral infection has also been identified as a risk factor for paracetamol hepatotoxicity [124] along with liver disease [125]. Interestingly, polymorphisms in the CYP2E1 enzyme causing altered acetylation status have been shown to be a factor influencing isoniazid hepatotoxicity [126, 127]. Conceivably, this may also be applicable to paracetamol with those individuals with a “rapid acetylator” phenotype may have accelerated production of the hepatotoxic NAPQI, however this needs to be substantiated further. Furthermore, the effect of age on these risk factors is not fully understood. Figure 3 describes the risk factors for paracetamol hepatotoxicity and the effect of age as a modifier of the risk factor. Increasing age is associated with increased time to presentation [128], resulting in poorer outcome. Interestingly, in rats the risk of hepatotoxicity from paracetamol decreases with increasing age [129]. It also must be acknowledged that elevated liver enzymes after exposure to paracetamol have occurred in adults who have none of the reported risk factors for paracetamol toxicity [89, 130].

The risk of hepatotoxicity from therapeutic doses of paracetamol in older people is not well defined. Older frail hospital in patients taking therapeutic paracetamol for five days do not have an increased risk of raised ALT compared to younger patient, although the clinical implications of such findings are not clear [131]. In people aged ≥ 65 years, the clinical increased risk of paracetamol hepatotoxicity is likely related to dosing that does not account for decreased liver volume with age, and to frailty and malnutrition [8]. Ageing and frailty are associated with a loss of reserves and increased state of vulnerability [132]. Therefore it is likely that the older frail patient will be at increased risk of DILI from therapeutic doses of medications. Changes in drug clearance in old age affect the formation and clearance of the toxic metabolites and therefore the susceptibility to DILI [67]. Interestingly one determinant of the variability in susceptibility to hepatotoxicity appears to be inflammatory
stress [1]. Subclinical chronic activation of the immune system in older people [133] is likely to result in decreased response to injury. Figure 4 summarises the paracetamol hepatotoxicity pathway and identifies potential parts of the pathway at which ageing may act to increase or decrease the susceptibility to toxicity. However, this is likely to vary between individuals.

5.6. Detection and Management of Paracetamol-Induced Liver Injury. Clinically, paracetamol overdose is associated with three main stages. The first lasts for approximately 24 hours and involves nonspecific gastrointestinal symptoms such as nausea, vomiting and abdominal pain with minimal elevation in serum liver enzyme concentrations. The second stage, from 24–72 hours, involves most notably the elevation of serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) concentrations released from damaged hepatocytes [134–136]. Serum ALT and total bilirubin are the most common biomarkers used to detect and manage hepatocellular injury [137]. Serum ALT is more liver specific than AST and is a very sensitive detector of hepatocellular necrosis; however, it cannot distinguish DILI from necrosis resulting from other causes such as viral hepatitis, alcohol consumption, or other unexplainable reasons [137–139]. In patients with a priori elevated transaminases, this is further complicated due to the lack of guidelines as to what contributes a significant increase [138]. In older people, reduced liver size may mean transaminases do not increase as substantially as for younger people [29, 140].

Serum paracetamol concentrations are used to guide treatment in overdose [142]. However, there is still limited evidence on the relationship between therapeutic serum paracetamol concentrations and risk of hepatotoxicity, as in older adults high serum concentrations are not necessarily associated with increased ALT levels [131]. The third stage of clinical paracetamol overdose develops in the next 24 hours, with the symptoms and outcome varying from full recovery to death depending on the severity of the liver damage [101]. Liver biopsy reveals a centrilobular necrosis, with perportal sparing and little or no inflammatory reaction [93, 134]. In severe cases, acute renal failure may occur [93]. Pharmacometabolonomics may help predict individuals at risk of paracetamol hepatotoxicity in the future [143].

5.7. Management and Treatment of Paracetamol-Induced Liver Injury. Early intervention is essential, as the aim of treatment is to prevent progression to acute liver failure. Paracetamol remains the only hepatotoxin to have effective pharmacotherapy, N-acetylcysteine (NAC), based on well-established nomograms [142]. The benefit of NAC extends those who have developed fulminant hepatic failure [144]. In older people, increased age is associated with increased time to presentation which may be explained in part by the higher proportion of accidental overdose in older patients [128]. By the time older adults present, NAC may no longer be beneficial despite being indicated for late presenters (10–24 hours after overdose) [144].

Adjunctive therapy such as corticosteroids or ursodeoxycholic acid is based on anecdotal evidence. The pharmacotherapy of end-stage liver disease (diuretics, beta-blockers) is the same as for other causes of liver disease [144]; however, this is not well described in ageing [86]. Older people do however suffer more ADRs to beta blockers and diuretics [145]. Studies in mice have indicated the usefulness of cimetidine both alone (two doses at 2 and 6 hours post paracetamol) and in combination therapy with NAC to reduce ALT/AST concentrations and increase hepatic GSH following paracetamol overdose [146]. Cimetidine may have limited use in hospitalised overdose patients with no effect on ALT/AST being observed if the cimetidine was given after 8 hours after overdose [147]. Additionally, cimetidine has anticholinergic side effects in older adults, which are well known to be associated with poorer functional outcomes [148, 149], further limiting the use of this adjuvant in older patients in clinical care.

6. Future Directions

A number of antioxidants have shown promise in protecting against paracetamol-induced liver injury. These include
Figure 4: The effect of age on the hepatotoxic pathway for paracetamol-induced liver injury. At therapeutic doses, paracetamol metabolised primarily in the liver via the Phase II metabolism (conjugation). A small amount of drug undergoes Phase I CYP450-(CYP)-mediated N-hydroxylation to form N-acetyl-p-aminobenzoquinone imine (NAPQI), a toxic metabolite which is conjugated with hepatic glutathione (GSH) and is neutralised. The major metabolites are excreted via the urine or bile by Phase III transporters. Saturation of conjugation pathways results in increased use of the CYP450 pathway, increased NAPQI formation, and increased depletion of hepatic glutathione. NAPQI can cause injury through direct cell stress, direct mitochondrial inhibition, or through immune reactions. Initial injury leads to mitochondrial dysfunction leading to either apoptosis of damaged cells, or necrosis with recovery, chronic liver injury or actual liver failure, and death as potential outcomes. Additionally, necrosis can stimulate the inflammatory response leading to cytokine release and further potentiation of the immune reaction. Ageing can act at multiple parts of the pathway to either increase ↑ or decrease ↓ susceptibility to hepatotoxicity. It must be noted, however, that this is likely to vary between individuals. The effect of ageing on Phase III transporters is somewhat unknown (?) in humans. Picture adapted from Russmann et.al., 2009 [141].

silymarin [150], resveratrol [151], Ukrain [152], Garcinia kola seed extract [153], Ginkgo biloba extract [154], L-carnitine [155] and oleanic acid [156]. All propose to protect from hepatotoxicity through reduction of oxidative stress mechanisms. However, it must be noted that while these compounds have shown promise in the laboratory setting in animal models, they all suffer the limitation of being given prior to paracetamol overdose. Interestingly, prostaglandin E2 given either before or 2 hours after paracetamol overdose showed significant hepatoprotective effects in mice [157]. However, their efficacy as a therapy postparacetamol treatment and in humans in the clinical setting still needs to be substantiated.

7. Conclusion

Optimal pharmacotherapy is determined when the pharmacokinetics and pharmacodynamics of the drug are understood. However, the age-related changes in pharmacokinetics and pharmacodynamics as well as the increased interindividual variation mean optimal dose selection is a challenge for prescribing in older adults. Paracetamol remains the first-line analgesic of choice for nonmalignant pain; however, dose reduction is mandated for frail older adults despite the pharmacokinetic and pharmacodynamic evidence for such a dose reduction being lacking. Animal studies have indicated a reduction in toxicity in old age, and this may possibly be the same for older frail adults. Understanding how ageing and frailty affect changes in drug clearance and toxicity will improve utilisation of this valuable analgesic and many other medicines by older adults.

Acknowledgments

The authors gratefully acknowledge the support of the Geoff and Elaine Penney Ageing Research Unit, Royal North Shore Hospital, and the National Health and Medical Research Council of Australia. S. J. Mitchell is supported by a National Health and Medical Research Council of Australia CJ Martin Early Career Fellowship (1016439).
References

[1] R. A. Roth and P. E. Ganey, "Intrinsic versus idiosyncratic drug-induced hepatotoxicity—two villains or one?" Journal of Pharmacology and Experimental Therapeutics, vol. 332, no. 3, pp. 692–697, 2010.

[2] S. J. Mitchell, S. N. Hilmer, and A. J. McLachlan, “Clinical pharmacology of analgesics in old age and frailty,” Reviews in Clinical Gerontology, vol. 19, no. 2, pp. 103–118, 2009.

[3] T. J. Moore, M. R. Cohen, and C. D. Furberg, “Serious adverse drug events reported to the food and drug administration, 1998–2005,” Archives of Internal Medicine, vol. 167, no. 16, pp. 1752–1759, 2007.

[4] P. A. Routledge, M. S. O’Mahony, and K. W. Woodhouse, “Adverse drug reactions in elderly patients,” British Journal of Clinical Pharmacology, vol. 57, no. 2, pp. 121–126, 2004.

[5] A. J. McLachlan, S. N. Hilmer, and D. G. Le Couteur, “Variability in response to medicines in older people: phenotypic and genotypic factors,” Clinical Pharmacology and Therapeutics, vol. 85, no. 4, pp. 431–433, 2009.

[6] L. P. Fried, C. M. Tangen, J. Walston et al., “Frailty in older adults: evidence for a phenotype,” Journals of Gerontology—Series A, vol. 56, no. 3, pp. M146–M156, 2001.

[7] J. Avorn and W. H. Shrank, “Adverse drug reactions in elderly people: a substantial cause of preventable illness,” British Medical Journal, vol. 336, no. 7650, pp. 956–957, 2008.

[8] S. N. Hilmer, A. J. McLachlan, and D. G. Le Couteur, “Clinical pharmacology in the geriatric patient,” Fundamental and Clinical Pharmacology, vol. 21, no. 3, pp. 217–230, 2007.

[9] H. A. Wynne, L. H. Cope, E. Mutch, M. D. Rawlins, K. W. Woodhouse, and O. F. W. James, “The effect of age upon liver volume and apparent liver blood flow in healthy men,” Hepatology, vol. 9, no. 2, pp. 297–301, 1989.

[10] A. J. McLean and D. G. Le Couteur, “Aging biology and geriatric clinical pharmacology,” Pharmacological Reviews, vol. 56, no. 2, pp. 163–184, 2004.

[11] A. Hämmerlein, H. Derendorf, and D. T. Lowenthal, “Pharmacokinetic and pharmacodynamic changes in the elderly. Clinical implications,” Clinical Pharmacokinetics, vol. 35, no. 1, pp. 49–64, 1998.

[12] S. N. Hilmer, "ADME-tox issues for the elderly," Expert Opinion on Drug Metabolism and Toxicology, vol. 4, no. 10, pp. 1321–1331, 2008.

[13] U. Klotz, "Pharmacokinetics and drug metabolism in the elderly," Drug Metabolism Reviews, vol. 41, no. 2, pp. 67–76, 2009.

[14] M. White, R. Roden, W. Minobe et al., “Age-related changes in beta-adrenergic neuroeffector systems in the human heart,” Circulation, vol. 90, no. 3, pp. 1225–1238, 1994.

[15] M. A. Smith and J. D. Gray, "Age-related differences in sensitivity to the antinociceptive effects of opioids in male rats. Influence of nociceptive intensity and intrinsic efficacy at the mu receptor," Psychopharmacology, vol. 156, no. 4, pp. 445–453, 2001.

[16] D. G. Le Couteur, V. C. Cogger, A. M. A. Markus et al., “Pseudocapillarization and associated energy limitation in the aged rat liver,” Hepatology, vol. 33, no. 3, pp. 537–543, 2001.

[17] M. T. Kinirons and P. Crome, “Clinical pharmacokinetic considerations in the elderly. An update,” Clinical Pharmacokinetics, vol. 33, no. 4, pp. 302–312, 1997.

[18] U. Klotz, "Effect of age on pharmacokinetics and pharmacodynamics in man," International Journal of Clinical Pharmacokinetics and Therapeutics, vol. 36, no. 11, pp. 581–585, 1998.

[19] C. A. Lang, S. Naryshkin, D. L. Schneider, B. J. Mills, and R. D. Lindeman, “Low blood glutathione levels in healthy aging adults,” Journal of Laboratory and Clinical Medicine, vol. 120, no. 5, pp. 720–725, 1992.

[20] D. G. Le Couteur, R. Fraser, V. C. Cogger, and A. J. McLean, “Hepatic pseudocapillarisation and atherosclerosis in ageing,” The Lancet, vol. 359, no. 9317, pp. 1612–1615, 2002.

[21] D. G. Le Couteur, R. Fraser, S. N. Hilmer, L. P. Rivory, and A. J. McLean, “The hepatic sinusoid in aging and cirrhosis: effects on hepatic substrate disposition and drug clearance,” Clinical Pharmacokinetics, vol. 44, no. 2, pp. 187–200, 2005.

[22] G. Lopez-Lluch, N. Hunt, B. Jones et al., “Calorie restriction induces mitochondrial biogenesis and bioenergetic efficiency,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 6, pp. 1768–1773, 2006.

[23] A. Warren, D. G. Le Couteur, R. Fraser, D. G. Bowen, G. W. McCaughan, and P. Bertolino, "I lymphocytes interact with hepatocytes through fenestrations in murine liver sinusoidal endothelial cells," Hepatology, vol. 44, no. 5, pp. 1182–1190, 2006.

[24] S. N. Hilmer and G. Ford, “General principles of pharmacology,” in Hazzard’s Geriatric Medicine & Gerontology, J. B. Halter, J. G. Ouslander, M. Tinetti et al., Eds., pp. 99–117, McGraw-Hill, New York, NY, USA, 6th edition, 2009.

[25] T. N. Tozer and M. Rowland, Introduction to Pharmacokinetics and Pharmacodynamics: The Quantitative Basis of Drug Therapy, Lippincott Williams & Wilkins, Philadelphia, Pa, USA, 2006.

[26] K. Turnheim, “When drug therapy gets old: pharmacokinetics and pharmacodynamics in the elderly,” Experimental Gerontology, vol. 38, no. 8, pp. 843–853, 2003.

[27] C. W. Bales and C. S. Ritchie, “Sarcopenia, weight loss, and nutritional frailty in the elderly,” Annual Review of Nutrition, vol. 22, pp. 309–323, 2002.

[28] H. A. Wynne, L. H. Cope, O. F. James, M. D. Rawlins, and K. W. Woodhouse, “The effect of age and frailty upon acetaminolide clearance in man,” Age and Ageing, vol. 18, no. 6, pp. 415–418, 1989.

[29] D. G. Le Couteur and A. J. McLean, “The aging liver: drug clearance and an oxygen diffusion barrier hypothesis,” Clinical Pharmacokinetics, vol. 34, no. 5, pp. 359–373, 1998.

[30] D. G. Le Couteur, L. P. Rivory, C. Yi, and S. M. Pond, “Aging, acute oxidative injury and hepatocellular glucose transport in the rat,” International Hepatology Communications, vol. 3, no. 5, pp. 244–253, 1995.

[31] Y. Ito, K. K. Sorensen, N. W. Bethea et al., “Age-related changes in the hepatic microcirculation in mice,” Experimental Gerontology, vol. 42, no. 8, pp. 789–797, 2007.

[32] R. Fraser, A. G. Bosanquet, and W. A. Day, “Filteration of chylomicrons by the liver may influence cholesterol metabolism and atherosclerosis,” Atherosclerosis, vol. 29, no. 2, pp. 113–123, 1978.

[33] R. Fraser, B. R. Dobbs, and G. T. Rogers, “Lipoproteins and the liver sive: the role of the fenestrated sinusoidal endothelium in lipoprotein metabolism, atherosclerosis, and cirrhosis,” Hepatology, vol. 21, no. 3, pp. 863–874, 1995.

[34] V. C. Cogger, D. G. Le Couteur et al., “Fenestrations in the liver sinusoidal endothelial cell,” in The Liver: Biology and Pathobiology, I. M. Arias, A. Wolfkoff, J. Boyer et al., Eds., pp. 387–404, John Wiley & Sons, Hoboken, NJ, USA, 2009.

[35] E. Wisse, “An electron microscopic study of the fenestrated endothelial lining of rat liver sinusoids,” Journal of Ultrastructure Research, vol. 31, no. 1-2, pp. 125–150, 1970.
[36] A. I. McLean, V. C. Cogger, G. C. Chong et al., “Age-related pseudocapillarization of the human liver,” Journal of Pathology, vol. 200, no. 1, pp. 112–117, 2003.

[37] D. G. Le Couteur, A. Warren, V. C. Cogger et al., “Old age and the hepatic sinusoid,” Anatomical Record, vol. 291, no. 6, pp. 672–683, 2008.

[38] J. Simon-Santamaria, I. Malovic, A. Warren et al., “Age-related changes in scavenger receptor-mediated endocytosis in rat liver sinusoidal endothelial cells,” Journals of Gerontology—Series A, vol. 65, no. 9, pp. 951–960, 2010.

[39] Z. X. Liu and N. Kaplowitz, “Role of innate immunity in acetaminophen-induced hepatotoxicity,” Expert Opinion on Drug Metabolism and Toxicology, vol. 2, no. 4, pp. 493–503, 2006.

[40] S. N. Hilmer, V. C. Cogger, and D. G. Le Couteur, “Basal activity of kupffer cells increases with old age,” Journals of Gerontology—Series A, vol. 62, no. 9, pp. 973–978, 2007.

[41] T. Yamano, S. D. Kosanke, and L. E. Rikans, “Attenuation of cadmium-induced liver injury in senescent male Fischer 344 rats: role of metallothionein and glutathione,” Toxicology and Applied Pharmacology, vol. 161, no. 3, pp. 225–230, 1999.

[42] S. K. Durham, A. Brouwer, R. J. Barelds, M. A. Horan, and D. L. Knoop, “Comparative endotoxin-induced hepatic injury in young and aged rats,” Journal of Pathology, vol. 162, no. 4, pp. 341–349, 1990.

[43] B. Vollmar, S. Pradarrutti, R. M. Nickels, and M. D. Menger, “Age-associated loss of immunomodulatory protection by granulocyte-colony stimulating factor in endotoxic rats,” Shock, vol. 18, no. 4, pp. 348–354, 2002.

[44] J. E. A. Leakey, H. C. Cunny, J. Bazare Jr. et al., “Effects of aging and caloric restriction on hepatic drug metabolizing enzymes in the Fisher 344 rat: I. the cytochrome P-450 dependent monooxygenase system,” Mechanisms of Ageing and Development, vol. 48, no. 2, pp. 145–155, 1989.

[45] E. A. Sotaniemi, A. J. Arranto, O. Pelkonen, and M. Pasanen, “Age and cytochrome P450-linked drug metabolism in humans: an analysis of 226 subjects with equal histopathologic conditions,” Clinical Pharmacology and Therapeutics, vol. 61, no. 3, pp. 331–339, 1997.

[46] D. L. Schmucker, “Liver function and phase I drug metabolism in the elderly: a paradox,” Drugs and Aging, vol. 18, no. 11, pp. 837–851, 2001.

[47] B. I. Gurlay, S. F. Gardner, M. A. Hubbard et al., “Clinical assessment of effects of botanical supplementation on cytochrome P450 phenotypes in the elderly: St John’s wort, garlic oil, Panax ginseng and Ginkgo biloba,” Drugs and Aging, vol. 22, no. 6, pp. 525–539, 2005.

[48] J. B. Schwartz, “Erythromycin breath test results in elderly, very elderly, and frail elderly persons,” Clinical Pharmacology and Therapeutics, vol. 79, no. 3, pp. 440–448, 2006.

[49] J. B. Schwartz and D. Verotta, “Population analyses of atorvastatin clearance in patients living in the community and in nursing homes,” Clinical Pharmacology and Therapeutics, vol. 86, no. 5, pp. 497–502, 2009.

[50] J. Posner, M. Danhof, M. W. E. Teunissen, D. D. Breimer, and P. D. Whiteman, “The disposition of antipyrine and its metabolites in young and elderly healthy volunteers,” British Journal of Clinical Pharmacology, vol. 24, no. 1, pp. 51–55, 1987.

[51] D. J. Greenblatt, M. Divoll, D. R. Abernethy, J. S. Harmatz, and R. I. Shader, “Antipyrine kinetics in the elderly: prediction of age-related changes in benzodiazepine oxidizing capacity,” Journal of Pharmacology and Experimental Therapeutics, vol. 220, no. 1, pp. 120–126, 1982.

[52] J. B. Schwartz, “The current state of knowledge on age, sex, and their interactions on clinical pharmacology,” Clinical Pharmacology and Therapeutics, vol. 82, no. 1, pp. 87–96, 2007.

[53] Y. K. J. Zhang, K. W. Saupe, and C. D. Klaassen, “Energy restriction does not compensate for the reduced expression of hepatic drug-processing genes in mice with aging,” Drug Metabolism and Disposition, vol. 38, no. 7, pp. 1122–1131, 2010.

[54] A. Parkinson, D. R. Mudra, C. Johnson, A. Dwyer, and K. M. Carroll, “The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes,” Toxicology and Applied Pharmacology, vol. 199, no. 3, pp. 193–209, 2004.

[55] X. Yang, B. Zhang, C. Molony et al., “Systematic genetic and genomic analysis of cytochrome P450 enzyme activities in human liver,” Genome Research, vol. 20, no. 8, pp. 1020–1036, 2010.

[56] O. T. Ayonrinde, G. J. Phelps, I. C. Hurley et al., “Paracetamol overdose and hepatotoxicity at a regional Australian hospital: a 4-year experience,” Internal Medicine Journal, vol. 35, no. 11, pp. 655–660, 2005.

[57] Z. Mokh Zain, A. I. Fathelrahman, and A. F. Ab Rahman, “Characteristics and outcomes of paracetamol poisoning cases at a general hospital in Northern Malaysia,” Singapore Medical Journal, vol. 47, no. 2, pp. 134–137, 2006.

[58] R. P. Myers, B. Li, A. Fong, A. A. M. Shaheen, and H. Quan, “Hospitalizations for acetaminophen overdose: a Canadian population-based study from 1995 to 2004,” BMC Public Health, vol. 7, 2007.

[59] G. Ostapowicz, R. J. Fontana, F. V. Schioedt et al., “Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States,” Annals of Internal Medicine, vol. 137, no. 12, pp. 947–954, 2002.

[60] P. Nourjah, S. R. Ahmad, C. Karwoski, and M. Willy, “Estimates of acetaminophen (paracetamol)-associated overdoses in the United States,” Pharmacoepidemiology and Drug Safety, vol. 15, no. 6, pp. 398–405, 2006.

[61] M. Ghandforoush-Sattari and S. Mashayekhi, “Admissions to the Cardiff Poisons Unit involving paracetamol poisoning (1989–2002),” Toxicological and Environmental Chemistry, vol. 90, no. 4, pp. 663–671, 2008.

[62] R. Shah, Z. Uren, A. Baker, and A. Majeed, “Trends in deaths from drug overdose and poisoning in England and Wales 1993–1998,” Journal of Public Health Medicine, vol. 23, no. 3, pp. 242–246, 2001.

[63] C. Xu, C. Li, and A.-N. Kong, “Induction of phase I, II and III drug metabolism/transport by xenobiotics,” Archives of Pharmacal Research, vol. 28, no. 3, pp. 249–268, 2005.

[64] J. M. Butler and E. J. Begg, “Free drug metabolic clearance in elderly people,” Clinical Pharmacokinetics, vol. 47, no. 5, pp. 297–321, 2008.

[65] J. S. Lee, W. O. Ward, D. C. Wolf et al., “Coordinated changes in xenobiotic metabolizing enzyme gene expression in aging male rats,” Toxicological Sciences, vol. 106, no. 1, pp. 263–283, 2008.

[66] M. Yamazaki, H. Suzuki, and Y. Sugiyama, “Recent advances in carrier-mediated hepatic uptake and biliary excretion of xenobiotics,” Pharmaceutical Research, vol. 13, no. 4, pp. 497–513, 1996.
[67] S. N. Hilmer, G. M. Shenfield, and D. G. Le Couteur, “Clinical implications of changes in hepatic drug metabolism in older people,” *Therapeutics and Clinical Risk Management*, vol. 1, no. 2, pp. 151–156, 2003.

[68] C. Marzolini, E. Paus, T. Buclin, and R. B. Kim, “Polymorphisms in human DRD1 (P-glycoprotein): recent advances and clinical relevance,” *Clinical Pharmacology and Therapeutics*, vol. 75, no. 1, pp. 13–33, 2004.

[69] J. S. Warrington, D. J. Greenblatt, and L. L. Von Moltke, “The effect of age on P-glycoprotein expression and function in the Fischer-344 rat,” *Journal of Pharmacology and Experimental Therapeutics*, vol. 309, no. 2, pp. 730–736, 2004.

[70] R. Toornvliet, B. N. M. van Berckel, G. Luurtsema et al., “Effect of age on functional P-glycoprotein in the blood-brain barrier measured by use of (R)-[11C]verapamil and positron emission tomography,” *Clinical Pharmacology and Therapeutics*, vol. 79, no. 6, pp. 540–548, 2006.

[71] R. B. Kim, B. Leake, M. Cvetkovic et al., “Modulation by drugs of human hepatic sodium-dependent bile acid transporter (sodium taurocholate cotransporting polypeptide) activity,” *Journal of Pharmacology and Experimental Therapeutics*, vol. 291, no. 3, pp. 1204–1209, 1999.

[72] G. López-Lluch, P. M. Irusta, P. Navas, and R. de Cabo, “Mitochondrial biogenesis and healthy aging,” *Experimental Gerontology*, vol. 43, no. 9, pp. 813–819, 2008.

[73] L. D. DeLeve and N. Kaplowitz, “Glutathione metabolism and its role in hepatotoxicity,” *Pharmacology and Therapeutics*, vol. 52, no. 3, pp. 287–305, 1991.

[74] M. J. Zamek-Gliszczynski, K. A. Ho L. E. Rikans, M. Nokubo, S. Kanai, and K. Kitani, “Diurnal glutathione and lipid peroxidation in the aging rat,” *Comparative Biochemistry and Physiology—Part B: Biochemistry and Physiology*, vol. 88, no. 1, pp. 177–180, 1987.

[75] L. E. Rikans and D. R. Moore, “Influence of aging on rat liver enzymes involved in glutathione synthesis and degradation,” *Archives of Gerontology and Geriatrics*, vol. 13, no. 3, pp. 263–270, 1991.

[76] G. A. Hazelton and C. A. Lang, “Glutathione contents of tissues in the aging mouse,” *Biochemical Journal*, vol. 188, no. 1, pp. 25–30, 1980.

[77] L. E. Rikans, M. Nokubo, S. Kanai, and K. Kitani, “Diurnal variation in hepatic glutathione content as a function of age,” *Drug Development Research*, vol. 26, no. 4, pp. 461–465, 1992.

[78] M. Erden-Inal, E. Sunal, and G. Kanbak, “Age-related changes in the glutathione redox system,” *Cell Biochemistry and Function*, vol. 20, no. 1, pp. 61–66, 2002.

[79] K. Mallikarjuna, K. R. Shanmugam, K. Nishanth et al., “Alcohol-induced deterioration in primary antioxidant and glutathione family enzymes reversed by exercise training in the liver of old rats,” *Alcohol*, vol. 44, no. 6, pp. 523–529, 2010.

[80] J. H. Suh, S. V. Shenvi, B. M. Dixon et al., “Decline in transcriptional activity of Nrf2 causes age-related loss of glutathione synthesis, which is reversible with lipoic acid,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 101, no. 10, pp. 3381–3386, 2004.

[81] S. N. Hilmer, V. C. Cogger, R. Fraser, A. J. McLean, D. Sullivan, and D. G. Le Couteur, “Age-related changes in the hepatic sinusoidal endothelium impede lipoprotein transfer in the rat,” *Hepatology*, vol. 42, no. 6, pp. 1349–1354, 2005.

[82] S. J. Mitchell, A. Huizer-Pajkos, V. C. Cogger et al., “Age-related pseudocapillarization of the liver sinusoidal endothelium impairs the hepatic clearance of acetaminophen in rats,” *The Journals of Gerontology—Series A*, vol. 66, no. 4, pp. 400–408, 2011.

[83] W. A. Al-Turk and S. J. Stohs, “Hepatic glutathione content and aryl hydrocarbon hydroxylase activity of acetaminophen-treated mice as a function of age,” *Drug and Chemical Toxicology*, vol. 4, no. 1, pp. 37–48, 1981.

[84] U. A. Boelsterli and P. L. K. Lim, “Mitochondrial abnormalities—a link to idiosyncratic drug hepatotoxicity?” *Toxicology and Applied Pharmacology*, vol. 220, no. 1, pp. 92–107, 2007.

[85] S. J. Mitchell and S. N. Hilmer, “Drug-induced liver injury in older people,” *Therapeutic Advances in Drug Safety*, vol. 1, no. 2, pp. 65–77, 2010.

[86] C. Collins and G. A. Starmer, “A review of the hepatotoxicity of paracetamol at therapeutic or near-therapeutic dose levels, with particular reference to alcohol abusers,” *Drug and Alcohol Review*, vol. 14, pp. 63–79, 1995.

[87] F. M. Gloth, “Concerns with chronic analgesic therapy in elderly patients,” *American Journal of Medicine*, vol. 101, no. 1, pp. 195–245, 1996.

[88] P. B. Watkins, N. Kaplowitz, J. T. Slattery et al., “Amino-transferase elevations in healthy adults receiving 4 grams of acetaminophen daily: a randomized controlled trial,” *Journal of the American Medical Association*, vol. 296, no. 1, pp. 87–93, 2006.

[89] D. Kwan, W. R. Bartle, and S. E. Walker, “Abnormal serum transaminases following therapeutic doses of acetaminophen in the absence of known risk factors,” *Digestive Diseases and Sciences*, vol. 40, no. 9, pp. 1951–1955, 1995.

[90] E. Björnsson and R. Olsson, “Suspected drug-induced liver fatalities reported to the WHO database,” *Digestive and Liver Disease*, vol. 38, no. 1, pp. 33–38, 2006.

[91] W. M. Lee, “Drug-induced hepatotoxicity,” *The New England Journal of Medicine*, vol. 349, no. 3, pp. 474–485, 2003.

[92] B. Ward and J. M. Alexander-Williams, “Paracetamol revisited: a review of the pharmacokinetics and pharmacodynamics,” *Acute Pain*, vol. 2, no. 3, pp. 139–149, 1999.

[93] D. J. Jollow, J. R. Mitchell, W. Z. Potter, D. C. Davis, J. R. Gillette, and B. B. Brodie, “Acetaminophen induced hepatic necrosis. II. Role of covalent binding in vivo,” *Journal of Pharmacology and Experimental Therapeutics*, vol. 187, no. 1, pp. 195–202, 1973.

[94] J. R. Mitchell, D. J. Jollow, W. Z. Potter, D. C. Davis, J. R. Gillette, and B. B. Brodie, “Acetaminophen induced hepatic necrosis. I. Role of drug metabolism,” *Journal of Pharmacology and Experimental Therapeutics*, vol. 187, no. 1, pp. 185–194, 1973.

[95] D. J. Jollow, S. S. Thorgersson, W. Z. Potter, M. Hashimoto, and J. R. Mitchell, “Acetaminophen induced hepatic necrosis. VI. Metabolic disposition of toxic and nontoxic doses of acetaminophen,” *Pharmacology*, vol. 12, no. 4–5, pp. 251–271, 1974.

[96] J. R. Mitchell, D. J. Jollow, W. Z. Potter, J. R. Gillette, and B. B. Brodie, “Acetaminophen induced hepatic necrosis. IV. Protective role of glutathione,” *Journal of Pharmacology and Experimental Therapeutics*, vol. 187, no. 1, pp. 211–217, 1973.

[97] J. G. M. Besems and N. P. E. Vermeulen, “Paracetamol (acetaminophen)-induced toxicity: molecular and biochemical mechanisms, analogues and protective approaches,” *Critical Reviews in Toxicology*, vol. 31, no. 1, pp. 55–138, 2001.
[99] A. K. Rowden, J. Norvell, D. L. Eldridge, and M. A. Kirk, "Acetaminophen poisoning," Clinics in Laboratory Medicine, vol. 26, no. 1, pp. 49–65, 2006.

[100] M. P. Holt and C. Ju, "Mechanisms of drug-induced liver injury," American Association of Pharmaceutical Scientists Journal, vol. 8, no. 1, pp. E48–E54, 2006.

[101] A. M. Larson, "Acetaminophen hepatotoxicity," Clinics in Liver Disease, vol. 11, no. 3, pp. 525–548, 2007.

[102] D. I. Antoine, D. P. Williams, and B. K. Park, "Understanding the role of reactive metabolites in drug-induced hepatotoxicity: state of the science," Expert Opinion on Drug Metabolism and Toxicology, vol. 4, no. 11, pp. 1415–1427, 2008.

[103] Z. X. Liu, S. Govindarajan, and N. Kaplowitz, "Innate immune system plays a critical role in determining the progression and severity of acetaminophen hepatotoxicity," Gastroenterology, vol. 127, no. 6, pp. 1760–1774, 2004.

[104] Y. Ishida, T. Kondo, T. Ohshima, H. Fujiwara, Y. Iwakura, and S. Mukaida, "A pivotal involvement of IFN-gamma in the pathogenesis of acetaminophen-induced acute liver injury," Federation of American Societies for Experimental Biology Journal, vol. 16, no. 10, pp. 1227–1236, 2002.

[105] C. R. Gardner, J. D. Laskin, D. M. Dambach et al., "Exaggerated hepatotoxicity of acetaminophen in mice lacking tumor necrosis factor receptor-1—potential role of inflammatory mediators," Toxicology and Applied Pharmacology, vol. 192, no. 2, pp. 119–130, 2003.

[106] M. Bourdi, Y. Masubuchi, T. P. Reilly et al., "Protection against acetaminophen-induced liver injury and lethality by interleukin 10: role of inducible nitric oxide synthase," Hepatology, vol. 35, no. 2, pp. 289–298, 2002.

[107] Y. Masubuchi, M. Bourdi, T. P. Reilly, M. L. M. Graf, J. W. George, and L. R. Pohl, "Role of interleukin-6 in hepatic heat shock protein expression and protection against acetaminophen-induced liver disease," Biochemical and Biophysical Research Communications, vol. 304, no. 1, pp. 207–212, 2003.

[108] S. D. Cohen and E. A. Khairallah, "Selective protein arylation and acetaminophen-induced hepatotoxicity," Drug Metabolism Reviews, vol. 29, no. 1-2, pp. 59–77, 1997.

[109] S. D. Cohen, N. R. Piumford, E. A. Khairallah et al., "Selective protein covalent binding and target organ toxicity," Toxicology and Applied Pharmacology, vol. 143, no. 1, pp. 1–12, 1997.

[110] D. Laskin and M. Pilaro, "Potential role of activated macrophages in acetaminophen hepatotoxicity. I. Isolation and characterization of activated macrophages from rat liver," Toxicology and Applied Pharmacology, vol. 86, no. 2, pp. 204–215, 1986.

[111] D. M. Dambach, L. M. Watson, K. R. Gray, S. K. Durham, and D. L. Laskin, "Role of CCR2 in macrophage migration into the liver during acetaminophen-induced hepatotoxicity in the mouse," Hepatology, vol. 35, no. 5, pp. 1093–1103, 2002.

[112] Y. Ishida, T. Kondo, T. Ohshima, H. Fujiwara, Y. Iwakura, and N. Mukaida, "A pivotal involvement of IFN-γ in the pathogenesis of acetaminophen-induced acute liver injury," Federation of American Societies for Experimental Biology Journal, vol. 16, no. 10, pp. 1227–1236, 2002.

[113] S. Michael, N. Pumford, P. Mayeux, M. Niesman, and J.6 Hinson, "Pretreatment of mice with macrophage inactivators decreases acetaminophen hepatotoxicity and the formation of reactive oxygen and nitrogen species," Hepatology, vol. 30, no. 1, pp. 186–195, 1999.

[114] C. Ju, T. P. Reilly, M. Bourdi et al., "Protective role of kuppfer cells in acetaminophen-induced hepatic injury in mice," Chemical Research in Toxicology, vol. 15, no. 12, pp. 1504–1513, 2002.

[115] D. Laskin, C. Gardner, V. Price, and D. Jollow, "Modulation of macrophage functioning abrogates the acute hepatotoxicity of acetaminophen," Hepatology, vol. 21, no. 4, pp. 1045–1050, 1995.

[116] N. Van Rooijen, N. Kors, M. V. d. Ende, and C. D. Dijkstra, "Depletion and repopulation of macrophages in spleen and liver of rat after intravenous treatment with liposome-encapsulated dichloromethylene diphosphonate," Cell and Tissue Research, vol. 260, no. 2, pp. 215–222, 1990.

[117] Y. Masubuchi, S. Sugiyama, and T. Horie, "Th1/Th2 cytokine balance as a determinant of acetaminophen-induced liver injury," Chemico-Biological Interactions, vol. 179, no. 2-3, pp. 273–279, 2009.

[118] M. P. Holt, H. Yin, and C. Ju, "Exacerbation of acetaminophen-induced disturbances of liver sinusoidal endothelial cells in the absence of Kupffer cells in mice," Toxicology Letters, vol. 194, no. 1-2, pp. 34–41, 2010.

[119] Y. Ito, N. W. Bethea, E. R. Abril, and R. S. McCaskey, "Early hepatic microvascular injury in response to acetaminophen toxicity," Microcirculation, vol. 10, no. 5, pp. 391–400, 2003.

[120] L. D. DeLeve, X. Wang, N. Kaplowitz, H. M. Shulman, J. A. Bart, and A. V. D. Hoek, "Sinusoidal endothelial cells as a target for acetaminophen toxicity: direct action versus requirement for hepatocyte activation in different mouse strains," Biochemical Pharmacology, vol. 53, no. 9, pp. 1339–1345, 1997.

[121] D. C. Whitcomb and G. D. Block, "Association of acetaminophen hepatotoxicity with fasting and ethanol use," Journal of the American Medical Association, vol. 272, no. 23, pp. 1845–1850, 1994.

[122] H. J. Zimmerman and W. C. Maddrey, "Acetaminophen (paracetamol) hepatotoxicity with regular intake of alcohol: analysis of instances of therapeutic misadventure," Hepatology, vol. 22, no. 3, pp. 767–773, 1995.

[123] K. S. Park, D. H. Sohn, R. L. Veech, and B. J. Song, "Translational activation of ethanol-inducible cytochrome P450 (CYP2E1) by isoniazid," European Journal of Pharmacology, vol. 248, no. 1, pp. 7–14, 1993.

[124] J. F. Maddox, C. J. Amuzie, M. Li et al., "Bacterial and viral-induced inflammation increases sensitivity to acetaminophen hepatotoxicity," Journal of Toxicology and Environmental Health—Part A, vol. 73, no. 1, pp. 58–73, 2010.

[125] R. P. Myers, A. A. M. Shaheen, B. Li, S. Dean, and H. Quan, "Impact of liver disease, alcohol abuse, and unintentional ingestions on the outcomes of acetaminophen overdose," Clinical Gastroenterology and Hepatology, vol. 6, no. 8, pp. 918–925, 2008.

[126] Y.-S. Huang, H.-D. Chern, W.-J. Su et al., "Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis," Hepatology, vol. 37, no. 4, pp. 924–930, 2003.

[127] W. C. Maddrey, "Drug-induced hepatotoxicity: 2005," Journal of Clinical Gastroenterology, vol. 39, no. 4, pp. S83–S89, 2005.

[128] L. E. Schmidt, "Age and paracetamol self-poisoning," Gut, vol. 54, no. 5, pp. 686–690, 2005.

[129] L. E. Rikans and D. R. Moore, "Acetaminophen hepatotoxicity in aging rats," Drug and Chemical Toxicology, vol. 11, no. 3, pp. 237–247, 1988.
